TWI365185B - Amidophenoxyindazoles useful as inhibitors of c-met - Google Patents

Amidophenoxyindazoles useful as inhibitors of c-met

Info

Publication number
TWI365185B
TWI365185B TW098123519A TW98123519A TWI365185B TW I365185 B TWI365185 B TW I365185B TW 098123519 A TW098123519 A TW 098123519A TW 98123519 A TW98123519 A TW 98123519A TW I365185 B TWI365185 B TW I365185B
Authority
TW
Taiwan
Prior art keywords
amidophenoxyindazoles
inhibitors
met
useful
amidophenoxyindazoles useful
Prior art date
Application number
TW098123519A
Other languages
English (en)
Chinese (zh)
Other versions
TW201006817A (en
Inventor
Tiechao Li
Mark Andrew Pobanz
Chuan Shih
Zhipei Wu
Wei Jennifer Yang
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TW201006817A publication Critical patent/TW201006817A/zh
Application granted granted Critical
Publication of TWI365185B publication Critical patent/TWI365185B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
TW098123519A 2008-07-24 2009-07-10 Amidophenoxyindazoles useful as inhibitors of c-met TWI365185B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27

Publications (2)

Publication Number Publication Date
TW201006817A TW201006817A (en) 2010-02-16
TWI365185B true TWI365185B (en) 2012-06-01

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098123519A TWI365185B (en) 2008-07-24 2009-07-10 Amidophenoxyindazoles useful as inhibitors of c-met

Country Status (36)

Country Link
US (2) US8030302B2 (ko)
EP (1) EP2310382B1 (ko)
JP (1) JP5414794B2 (ko)
KR (1) KR101334456B1 (ko)
CN (1) CN102105462B (ko)
AR (1) AR074632A1 (ko)
AT (1) ATE546444T1 (ko)
AU (1) AU2009274256B2 (ko)
BR (1) BRPI0916286B8 (ko)
CA (1) CA2731773C (ko)
CL (1) CL2011000134A1 (ko)
CO (1) CO6351737A2 (ko)
CR (1) CR20110046A (ko)
CY (1) CY1112595T1 (ko)
DK (1) DK2310382T3 (ko)
DO (1) DOP2011000009A (ko)
EA (1) EA018385B1 (ko)
EC (1) ECSP11010778A (ko)
ES (1) ES2379587T3 (ko)
HK (1) HK1155172A1 (ko)
HR (1) HRP20120202T1 (ko)
IL (1) IL210490A (ko)
JO (1) JO2788B1 (ko)
MA (1) MA32594B1 (ko)
MX (1) MX2011000925A (ko)
MY (1) MY163852A (ko)
NZ (1) NZ590013A (ko)
PE (1) PE20110150A1 (ko)
PL (1) PL2310382T3 (ko)
PT (1) PT2310382E (ko)
RS (1) RS52261B (ko)
SI (1) SI2310382T1 (ko)
SV (1) SV2011003816A (ko)
TW (1) TWI365185B (ko)
WO (1) WO2010011538A1 (ko)
ZA (1) ZA201100219B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011119478A (ru) 2008-10-14 2012-11-27 Нин Си Соединения и способы применения
JP5583751B2 (ja) 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
WO2012121939A2 (en) * 2011-03-04 2012-09-13 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
WO2013169532A1 (en) * 2012-05-09 2013-11-14 Eli Lilly And Company Anti-c-met antibodies
US9790206B2 (en) * 2013-02-27 2017-10-17 Array Biopharma Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
EP3134088B1 (en) 2014-04-22 2019-04-10 Calitor Sciences, LLC Bicylcic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
JP2019511541A (ja) * 2016-04-15 2019-04-25 イーライ リリー アンド カンパニー 結腸直腸癌の処置における使用のためのラムシルマブとメレスチニブとの組み合わせ
MX2018014863A (es) 2016-06-02 2019-09-11 Immunocore Ltd Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
EP3490676A1 (en) * 2016-07-29 2019-06-05 Eli Lilly and Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
ES2866348T3 (es) 2016-11-16 2021-10-19 Lilly Co Eli Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
US20200054616A1 (en) 2016-11-16 2020-02-20 Eli Lilly And Company Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
WO2019101178A1 (zh) 2017-11-24 2019-05-31 南京明德新药研发股份有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
CA3072169C (en) 2018-03-08 2022-04-19 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
EP3842425B1 (en) * 2018-08-24 2024-05-22 TransThera Sciences (Nanjing), Inc. Novel quinoline derivative inhibitor
CN112739691B (zh) * 2018-09-03 2023-05-23 泰励生物科技(上海)有限公司 用作抗癌药的trk抑制剂
KR20220059386A (ko) 2019-09-06 2022-05-10 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
KR20220170766A (ko) * 2021-06-22 2022-12-30 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
ES2268015T3 (es) * 2001-05-18 2007-03-16 Srl, Inc. Procedimiento de inmunoensayo.
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
CA2503646C (en) 2002-10-28 2011-09-27 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
ES2300768T3 (es) * 2003-07-17 2008-06-16 Invitrogen Dynal As Procedimiento para preparar particulas magneticas recubiertas.
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
DK1966214T3 (en) 2005-12-21 2017-02-13 Janssen Pharmaceutica Nv TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
US9738745B2 (en) * 2006-06-29 2017-08-22 Life Technologies As Particles containing multi-block polymers
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
PT2084162E (pt) 2006-10-23 2012-10-09 Sgx Pharmaceuticals Inc Triazoles bicíclicos como moduladores de proteína quinase
US8076521B2 (en) 2007-06-27 2011-12-13 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Also Published As

Publication number Publication date
KR101334456B1 (ko) 2013-11-29
TW201006817A (en) 2010-02-16
IL210490A (en) 2013-06-27
KR20110022691A (ko) 2011-03-07
MA32594B1 (fr) 2011-09-01
AU2009274256A1 (en) 2010-01-28
CN102105462B (zh) 2014-07-23
JP2011529054A (ja) 2011-12-01
US8030302B2 (en) 2011-10-04
CR20110046A (es) 2011-04-27
ATE546444T1 (de) 2012-03-15
MY163852A (en) 2017-10-31
JP5414794B2 (ja) 2014-02-12
PL2310382T3 (pl) 2012-07-31
US20100022529A1 (en) 2010-01-28
JO2788B1 (en) 2014-03-15
CL2011000134A1 (es) 2011-07-08
EA201170252A1 (ru) 2011-06-30
DOP2011000009A (es) 2011-03-31
AR074632A1 (es) 2011-02-02
NZ590013A (en) 2012-06-29
EP2310382B1 (en) 2012-02-22
USRE43878E1 (en) 2012-12-25
SI2310382T1 (sl) 2012-04-30
MX2011000925A (es) 2011-03-21
DK2310382T3 (da) 2012-03-26
RS52261B (en) 2012-10-31
ECSP11010778A (es) 2011-02-28
PT2310382E (pt) 2012-04-11
BRPI0916286B8 (pt) 2021-05-25
CO6351737A2 (es) 2011-12-20
CN102105462A (zh) 2011-06-22
EA018385B1 (ru) 2013-07-30
BRPI0916286B1 (pt) 2019-10-08
IL210490A0 (en) 2011-03-31
HK1155172A1 (en) 2012-05-11
PE20110150A1 (es) 2011-03-07
AU2009274256B2 (en) 2013-07-11
ZA201100219B (en) 2012-06-27
HRP20120202T1 (hr) 2012-03-31
ES2379587T3 (es) 2012-04-27
SV2011003816A (es) 2011-03-17
EP2310382A1 (en) 2011-04-20
WO2010011538A1 (en) 2010-01-28
CY1112595T1 (el) 2016-02-10
CA2731773A1 (en) 2010-01-28
CA2731773C (en) 2013-03-12

Similar Documents

Publication Publication Date Title
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
HK1223272A1 (zh) 程序性壞死的小分子抑制劑
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
ZA201104749B (en) Benzonaphtyridine compounds used as inhibitors of autotaxin
IL207100A0 (en) 2-amino-quinoline derivatives useful as inhibitors of b-secretase (bace)
GB0621607D0 (en) Inhibitors of c-Met
EP2249650A4 (en) ANILINOPYRIDINE AS A FAK HEMMER
ZA201100898B (en) Novel inhibitors
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
HK1161680A1 (en) Pyrazolylaminopyridines as inhibitors of fak fak
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
PT2297115E (pt) Derivados de quinazolina
HK1160925A1 (zh) 組織蛋白酶 的用途
IL208916A0 (en) Inhibitors of jnk
EP2382974A4 (en) USE OF CYCLOSQUARAMIDE COMPOUNDS AS ANTITUMOR AGENTS
GB0821710D0 (en) Derivatives of dihydroindolone
PL386302A1 (pl) Nowa pochodna izotiazolopirydyny
GB0816125D0 (en) Novel inhibitors
GB0621980D0 (en) Inhibitors of c-Met

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees